CRSP

Crispr Therapeutics
$54.11
+$2.64 (+5.13%)Oct 28, 2026
3.0FairMoatMint rating

MoatMint rates Crispr Therapeutics (CRSP) 3.0 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 1.5 out of 10.

Return-41.8%5YRange $32.66 - $93.00
$100$75.3$50.4$25.4Nov 21Sep 25Oct 26

Key metrics

The numbers that frame CRSP today
Market cap
$5.23B
Gross margin
100%
EV / Sales
426.9
ROIC
-18%
Div yield
0%
Debt / equity
0.4
52wk Low
$44.12
52wk High
$65.98

CRSP stock rating

How CRSP scores on quality, value, growth, momentum and financial health
3.0out of 10
Fair overallFair business, expensive price
Quality1.5
Growth4.5
Momentum6.6
Value2.3
Financial Health5.1

Growth

Revenue and earnings trend for CRSP
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about CRSP
Is Crispr Therapeutics a good buy?
Hold. Crispr Therapeutics has strong momentum, but poor quality makes the setup mixed. Growth looks mixed. The support signal is useful, but not decisive. We think Crispr Therapeutics is selling at a very high price.
What is the market capitalization of CRSP?
Crispr Therapeutics's market capitalization is $5.23B.
What is the 52-week high for CRSP stock?
The 52-week high for Crispr Therapeutics is $65.98. The current close of $54.11 is 18% below that high.
What is the 52-week low for CRSP stock?
The 52-week low for Crispr Therapeutics is $44.12. The current close of $54.11 is 22.6% above that low.
Does CRSP stock pay dividends?
Crispr Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for CRSP?
Crispr Therapeutics's Debt / Equity ratio is 0.45.